StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a report released on Saturday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Price Performance
Shares of EVOK stock opened at $0.47 on Friday. The stock has a 50-day moving average of $0.56 and a 200-day moving average of $0.85. The stock has a market cap of $3.99 million, a PE ratio of -0.20 and a beta of 0.38. Evoke Pharma has a one year low of $0.41 and a one year high of $2.40.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last issued its quarterly earnings data on Thursday, March 14th. The specialty pharmaceutical company reported ($0.59) EPS for the quarter. The company had revenue of $1.68 million for the quarter. Evoke Pharma had a negative return on equity of 517.99% and a negative net margin of 150.43%.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Further Reading
- Five stocks we like better than Evoke Pharma
- Dividend Capture Strategy: What You Need to Know
- Garmin Navigates to New Highs Driven By Wearables Trend
- What Does Downgrade Mean in Investing?
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- Investing In Automotive Stocks
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
